Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

Published:2024-08 Issue: Volume:977 Page:176725
ISSN:0014-2999
Container-title:European Journal of Pharmacology
language:en
Short-container-title:European Journal of Pharmacology

Author:

Geng Wujun,Thomas Holly,Chen Zhiyuan,Yan Zhixiu,Zhang Pujuan,Zhang Meiying,Huang Weixue,Ren Xiaomei,Wang Zhen,Ding Ke,Zhang Jinwei^ORCID

Funder

The Royal Society

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference100 articles.

1. Safety and efficacy of T-DM1 plus neratinib in patients with metastatic HER2-positive breast cancer: NSABP foundation trial FB-10;Abraham;J. Clin. Oncol.,2019

2. Paired overexpression of ErbB3 and Sox 10 in pilocytic astrocytoma;Addo-Yobo;J. Neuropathol. Exp. Neurol.,2006

3. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?;Arnould;Br. J. Cancer,2006

4. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium;Balko;Proc. Natl. Acad. Sci. U.S.A.,2011

5. Lysosome-targeting chimaeras for degradation of extracellular proteins;Banik;Nature,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP